Alnylam Achieves Full-Year Profitability, Reports Strong 2025 Results, and Issues Robust 2026 Guidance
Summary
Alnylam Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, achieving GAAP and non-GAAP profitability for the first time, driven by significant product revenue growth, and provided robust 2026 revenue guidance.
Key Events
-
Achieved Full-Year Profitability
Alnylam reported GAAP and non-GAAP profitability for the full year ended December 31, 2025, with GAAP net income of $313.7 million and non-GAAP net income of $683.6 million, a significant turnaround from losses in 2024.
-
Strong 2025 Product Revenue Growth
Global net product revenues reached $2.987 billion for the full year 2025, representing 81% growth compared to 2024, primarily driven by the landmark approval and uptake of AMVUTTRA for ATTR-CM.
-
Robust 2026 Revenue Guidance
The company provided strong 2026 financial guidance, projecting total net product revenues of $4.9 billion to $5.3 billion, indicating an expected growth of 64% to 77% over 2025.
-
Advancing Pipeline and Strategic Investments
Alnylam initiated new Phase 1 and Phase 2 clinical trials for ALN-4324 (type 2 diabetes) and ALN-2232 (obesity), advanced two new programs, and announced a $250 million investment to expand its manufacturing facility.
Analysis
This 8-K details Alnylam's impressive financial performance for 2025, highlighted by achieving full-year GAAP and non-GAAP profitability, a significant milestone for a biotech company. The substantial 81% year-over-year growth in global net product revenues, reaching nearly $3 billion, was primarily fueled by the strong uptake of AMVUTTRA. The company also issued optimistic 2026 financial guidance, projecting further product revenue growth of 64% to 77%, indicating continued strong commercial momentum. Additionally, Alnylam provided updates on its pipeline, including new clinical trial initiations and upcoming data readouts, reinforcing its commitment to innovation. The planned $250 million investment in manufacturing expansion further supports future growth and cost efficiency. Investors should view these results and outlook as highly positive, demonstrating successful commercial execution and a promising development pipeline.
At the time of this filing, ALNY was trading at $317.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.6B. The 52-week trading range was $205.87 to $495.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.